BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 27156424)

  • 1. Pulmonary dose-volume predictors of radiation pneumonitis following stereotactic body radiation therapy.
    Harder EM; Park HS; Chen ZJ; Decker RH
    Pract Radiat Oncol; 2016; 6(6):e353-e359. PubMed ID: 27156424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive parameters of symptomatic radiation pneumonitis following stereotactic or hypofractionated radiotherapy delivered using volumetric modulated arcs.
    Bongers EM; Botticella A; Palma DA; Haasbeek CJ; Warner A; Verbakel WF; Slotman B; Ricardi U; Senan S
    Radiother Oncol; 2013 Oct; 109(1):95-9. PubMed ID: 24183862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for radiation pneumonitis after stereotactic radiation therapy for lung tumours: clinical usefulness of the planning target volume to total lung volume ratio.
    Ueyama T; Arimura T; Takumi K; Nakamura F; Higashi R; Ito S; Fukukura Y; Umanodan T; Nakajo M; Koriyama C; Yoshiura T
    Br J Radiol; 2018 Jun; 91(1086):20170453. PubMed ID: 29565649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Low dose volume histogram analysis of the lungs in prediction of acute radiation pneumonitis in patients with esophageal cancer treated with three-dimensional conformal radiotherapy].
    Shen WB; Zhu SC; Gao HM; Li YM; Liu ZK; Li J; Su JW; Wan J
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):45-9. PubMed ID: 23648300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
    Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
    Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel.
    Barriger RB; Fakiris AJ; Hanna N; Yu M; Mantravadi P; McGarry RC
    Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1381-6. PubMed ID: 20231061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy.
    Ricardi U; Filippi AR; Guarneri A; Giglioli FR; Mantovani C; Fiandra C; Anglesio S; Ragona R
    Acta Oncol; 2009; 48(4):571-7. PubMed ID: 19031164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy.
    Barriger RB; Forquer JA; Brabham JG; Andolino DL; Shapiro RH; Henderson MA; Johnstone PA; Fakiris AJ
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):457-62. PubMed ID: 21035956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis.
    Claude L; PĂ©rol D; Ginestet C; Falchero L; Arpin D; Vincent M; Martel I; Hominal S; Cordier JF; Carrie C
    Radiother Oncol; 2004 May; 71(2):175-81. PubMed ID: 15110451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung.
    Baker R; Han G; Sarangkasiri S; DeMarco M; Turke C; Stevens CW; Dilling TJ
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):190-5. PubMed ID: 22929858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic analysis of radiation pneumonitis: carbon-ion radiotherapy in patients with locally advanced lung cancer.
    Hayashi K; Yamamoto N; Karube M; Nakajima M; Matsufuji N; Tsuji H; Ogawa K; Kamada T
    Radiat Oncol; 2017 May; 12(1):91. PubMed ID: 28558766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer.
    Kim TH; Cho KH; Pyo HR; Lee JS; Zo JI; Lee DH; Lee JM; Kim HY; Hwangbo B; Park SY; Kim JY; Shin KH; Kim DY
    Radiology; 2005 Apr; 235(1):208-15. PubMed ID: 15703313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation.
    Ren C; Ji T; Liu T; Dang J; Li G
    Radiat Oncol; 2018 Apr; 13(1):69. PubMed ID: 29661254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exclusion of emphysematous lung from dose-volume estimates of risk improves prediction of radiation pneumonitis.
    Uchida Y; Tsugawa T; Tanaka-Mizuno S; Noma K; Aoki K; Shigemori W; Nakagawa H; Kinose D; Yamaguchi M; Osawa M; Ogawa E; Nakano Y
    Radiat Oncol; 2017 Oct; 12(1):160. PubMed ID: 28969651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy.
    Liu H; Zhang X; Vinogradskiy YY; Swisher SG; Komaki R; Chang JY
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):1017-23. PubMed ID: 22543216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of radiation pneumonitis in patients receiving taxane-based trimodality therapy for locally advanced esophageal cancer.
    Shaikh T; Churilla TM; Monpara P; Scott WJ; Cohen SJ; Meyer JE
    Pract Radiat Oncol; 2016; 6(6):388-394. PubMed ID: 27025161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy.
    Borst GR; Ishikawa M; Nijkamp J; Hauptmann M; Shirato H; Onimaru R; van den Heuvel MM; Belderbos J; Lebesque JV; Sonke JJ
    Radiother Oncol; 2009 Jun; 91(3):307-13. PubMed ID: 19321217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
    Feddock J; Arnold SM; Shelton BJ; Sinha P; Conrad G; Chen L; Rinehart J; McGarry RC
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1325-31. PubMed ID: 23265574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancer.
    Nakamura M; Nishimura H; Nakayama M; Mayahara H; Uezono H; Harada A; Hashimoto N; Ejima Y; Ishihara T; Sasaki R
    Br J Radiol; 2016 Dec; 89(1068):20160560. PubMed ID: 27805837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of radiation pneumonitis after thoracic irradiation: Dose-volume correlates.
    Schallenkamp JM; Miller RC; Brinkmann DH; Foote T; Garces YI
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):410-6. PubMed ID: 17236964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.